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normal neutral sphingomyelinase activity
(Table 1). SM deacylase activity could
not be observed (not shown).
AD sample no. 4 emerged as a special
specimen. We never found free fatty
acids to be generated from PC in other
skin samples, but surprisingly, chronic
dermatitis sample no. 4 hydrolyzed C5-
PC (Figure 1). When 1,2-bis C11-PC in
which both of the esterified fatty acids are
labelled was used as the substrate, C11-
free fatty acid was detected (Figure 2). In
contrast to all of the other AD specimens,
sample no. 4 generated some products
detectable between the plate origin and
1,2-bis C11-PC. These bands might corre-
spond to C11-SM or to lyso-PC. The faint
band intensities, however, point to rather
low amounts as products of 1,2-bis C11-
PC containing only one labelled fatty
acid reveal increased emission intensities
as compared to 1,2-bis C11-PC in which
the adjacent fluorophores quench them-
selves. The more intense emission of the
free fatty acid might indicate that both of
the acyl-chains were hydrolyzed but
mostly not re-esterified (Figure 2).
Missing transacylase in a normal
skin specimen indicates that the loss
of this enzymatic activity is not suffi-
cient for AD development. On the other
hand, one of the AD samples (no. 4)
might contain some transacylase activ-
ity that does not protect against AD.
Conversely interpreted, the one excep-
tional normal individual might be at
risk for AD development, and the
special AD patient might await remis-
sion of disease.
In conclusion, we found that AD
skin may be associated with a lack of
PC-SM transacylase activity.
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TO THE EDITOR
Skin cancer results from chronic solar
exposure, especially in fair-skinned
people (Armstrong et al., 1997). The
International Agency for Research on
Cancer (IARC) assessed the role of
sunscreens in skin cancer prevention
and concluded that ‘‘There is limited
evidence in humans for a cancer pre-
ventive effect of the topical use of
sunscreen formulations against squa-
mous-cell carcinoma of the skin’’
(IARC, 2001). Furthermore, there was
‘‘inadequate evidence’’ for any preven-
tive effects against basal cell carcinoma
and malignant melanoma.
Photocarcinogenesis involves DNA
photodamage, inadequate DNA repair,
probable failure of apoptosis, mutation
(Wikonkal and Brash, 1999), clonal
expansion of mutated cells (Brash
et al., 2005), and UVR-induced immuno-
suppression (Ullrich, 2002; Ullrich
et al., 2002). Most human photobiology
research is with a single erythemal
exposure that is not representative of
the effects of repeated sub-erythemal
exposure, which may initiate adaptive
responses such as tanning and DNA
repair (Sheehan et al., 1998, 2002; Agar
Abbreviations: CPD, cyclobutane pyrimidine dimer; LC, Langerhans cell; MED, minimal erythema dose;
SBC, sunburn cell; SSR, solar simulating radiation; TT, thymine dimer
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and Young, 2005). Many earlier repeat
exposure studies were performed with
non-solar spectra, but more recent work
has been performed with solar simulat-
ing radiation (SSR) (Seite et al., 2006).
We studied the effects of 11 con-
secutive daily sub-erythemal exposures
of SSR on buttock skin of six healthy
sun sensitive skin types 1/II (20–30
years) (Materials and Methods and
Table S1). A standard dose was given
on each exposure that represented 0.52
or 0.65 minimal erythema doses (MED)
depending on the MED of the volun-
teer. We assessed erythema daily and,
on days 5, 11, and 12 (24 hours after
last exposure), end points relevant in
skin cancer, including thymine dimers
(TT), p53 and Bcl2 protein expression
that regulates apoptosis, apoptotic sun-
burn cells (SBC), Langerhans cell (LC)
depletion, and epidermal turnover.
Standard quantitative histological and
immunohistochemical techniques were
used and are described in more detail
in the Supplementary Material (Materi-
als and Methods and Table S2). We
also evaluated the effects of a broad-
spectrum (4* UVA) daily-care low
sun protection factor (7.5) sunscreen
(2 mg/cm2) with 6% polysilicone-15
(Parsol SLX) as a UVB filter and 2%
butyl methoxydibenzoylmethane (Parsol
1789) as a UVA filter (see Figure S1 in
Materials and Methods for absorption
profile). The study, approved by the
Ethics Committee of St Thomas’ Hospi-
tal London, was performed according to
the Declaration of Helsinki Principles
and volunteers gave written informed
consent.
EFFECTS OF REPEATED SUB-ERYTHE-
MAL SSR AND MODIFICATION BY
THE SUNSCREEN
Erythema accumulated on the vehicle
control sites but not on the sunscreen
sites (Figure 1a). At day 12, the vehicle
site showed a florid erythema and
considerably more DNA damage than
the sunscreen site (Figure 1b).
Overall, sunscreen-treated sites
showed much less DNA damage (TT)
than the vehicle sites at all time points
(Po0.01–0.03) (Figure 2a). P53 expres-
sion was very low on all sunscreen-
treated sites (Figure 2b). Much higher
expression was seen on the vehicle sites
but with high inter-personal variation.
Significant protection (Po0.01) was
only seen at day 11. There was no
difference in Bcl2 expression between
the 0 MED control and any other site
(data not shown) and no SBC were seen
on any site. There was a time-depen-
dent trend for depletion of LC with the
vehicle that was significantly different
from 0 MED at days 11 (P¼0.02) and
12 (Po0.01) (Figure 2c). The sunscreen
sites were not significantly different
from the 0 MED control at any time
point. Sunscreen protection, compared
with vehicle, was significant at days 5
(P¼0.04) and 12 (Po0.01). There was
a high inter-personal variation in an
immunomarker of epidermal turnover
(MIB1/Ki-67), even with the 0 MED
control site (data not shown). Sunscreen
values were lower but not significantly
so. The mean number of viable cell
layers was not affected (data not shown)
by any treatment. Our data can be
compared with another study (Seite
et al., 2006) that assessed the effects
of nine daily exposures of 0.5 and
0.75 MED SSR (but with a lower UVB
content than our spectrum). This work
also showed increased p53 expression
and LC depletion. The authors reported
SBC induction, but this was only up to
1.5 SBC/cm that is unlikely to be
biologically significant.
POSSIBLE ROLE OF SUNSCREENS IN
THE PREVENTION OF CHRONIC
PHOTODAMAGE
Daily sub-erythemal SSR causes signifi-
cant clinical, cellular, and molecular
damage in skin types I/II and that can
be inhibited by the use of a broad-
spectrum daily-care sunscreen with a
low sun protection factor and 4* UVA
protection.
The cyclobutane pyrimidine dimer
(CPD), of which TT is one type, is
important for skin cancer (Jans et al.,
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Figure 1. The accumulation of clinical and molecular photodamage is prevented by the daily use of a
sunscreen. (a) Erythema, assessed by reflectance spectroscopy, after daily sub-erythemal exposure is
prevented by sunscreen application. Note that the eye starts to detect erythema at an erythema index (EI)
of about 50, (b) TT on day 12 from one volunteer, 24 hours after final irradiation showing vehicle control
and sunscreen-treated skin. Bar¼ 50mm.
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2005). Comparisons at all three time
points showed a very significant
(P-value generally o0.01) reduction of
TT in sunscreen groups compared with
their vehicle controls. In another study,
a sun protection factor of 15 gave good
protection against TT when applied
before four daily doses of 2 MED SSR
(Al Mahroos et al., 2002). There is
considerable evidence that the CPD,
and the TT in particular, initiates
erythema and our data support this.
Furthermore, CPD are able to cause
potentially carcinogenic mutations,
which can be prevented by sunscreens
in mice (Ananthaswamy et al., 2002).
The cellular response to CPD is
regulated by p53 with two main pro-
tective outcomes; DNA repair or apop-
tosis (SBC) (Melnikova and Anantha-
swamy, 2005). p53 expression has
recently been reported as a possible
biomarker for actinic keratoses, which
may progress to squamous cell carci-
noma (Einspahr et al., 2006). Trans-
genic mouse studies have shown that
failure to repair DNA photodamage, in
particular transcription-coupled repair,
results in SBC formation (Brash et al.,
2001) and that normal p53 status results
in optimal SBC response (Ziegler et al.,
1994). Furthermore, other studies show
that the CPD is the putative lesion for
SBC (Jans et al., 2005). No treatment
had any effect on constitutive Bcl2
expression. The control vehicle p53
data showed high SDs, especially on
day 12, which was the consequence of
differing individual time course,
whereas p53 expression on all the
sunscreen sites was very low. Signifi-
cant (Po0.01) protection by the sunsc-
reen was only achieved on day 11. SBC
are normally seen in human epidermis
about 24 hours after acute erythemal
UVR (Sheehan and Young, 2002), but
SBC were not observed in the vehicle
control sites which is surprising given
the presence of CPD and p53 expres-
sion (Washio et al., 1999; Sheehan and
Young, 2002). However, mouse studies
have shown that chronic irradiation
(three times per week) results in a loss
of the apoptotic response within 7 days
which is associated with the loss of the
Fas-ligand, which interacts with Fas
(CD95) to induce apoptosis (Ouhtit
et al., 2000). Single exposure studies
on human buttock skin have shown that
UVB downregulates Fas-ligand and the
receptor for tumor necrosis factor-re-
lated apoptosis-inducing ligand (Bach-
mann et al., 2001). UVR-induced
resistance to apoptosis may serve to
maintain a viable and proliferating
epidermis.
The depletion of antigen-presenting
LC, along with the influx of CD11bþ
macrophages, is important in the im-
munomodulatory effects of UVR (Meu-
nier et al., 1995). The vehicle control
data show a time-dependent depletion
of LC that was prevented by the
sunscreen.
The MIB1 data suggest that all
treatments stimulated some epidermal
proliferation, although the large inter-
personal variation meant no treatment
was significantly different from any
other or the 0 MED control. This was
supported by the epidermal layer data.
The sunscreen sites received an
estimated B0.1 MED/day that resulted
in some accumulation of CPD. Thus,
avoiding sunburn to reduce skin cancer
risk does not necessarily prevent DNA
photodamage and indicates the impor-
tance of CPD repair in the prevention of
skin cancer especially in the absence of
an apoptotic response after repeated
SSR exposure. The minimization of skin
cancer risk in susceptible populations,
especially where some degree of solar
exposure is unavoidable, may ulti-
mately require the incorporation of
DNA repair enhancement technology
in sunscreens (Yarosh et al., 2005).
In conclusion, daily sub-erythemal
SSR exposure in skin types I/II results
in clinical, cellular, and molecular
damage. Much of this damage, and in
some cases all of it, can be inhibited by
0
1
2
3
4
5a
b
c
0
20
40
60
80
100
0
2
4
6
8
5d-SS 5d-VC 11d-SS 11d-VC 12d-SS 12d-VC 0MED
5d-SS 5d-VC 11d-SS 11d-VC 12d-SS 12d-VC 0MED
5d-SS 5d-VC 11d-SS 11d-VC 12d-SS 12d-VC 0MED
In
de
x+
SD
In
de
x+
SD
In
de
x+
SD
Figure 2. Daily sunscreen use abrogates DNA and immunological damage. Sunscreen prevents the
epidermal effects of repeated daily sub-erythemal SSR exposure on (a) the accumulation of TT where 50%
of cells reached a given scoring index (see Supplementary Material); very similar results were observed
for an assessment of 25% of cells, (b) the accumulated expression of normal p53 protein, (c) the gradual
time-dependent loss of LC in the vehicle control group. SS¼ sunscreen; VC¼ vehicle control.
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a low sun protection factor sunscreen
that may be effective in the prevention
of long-term photodamage, including
skin cancer. However, a preventive role
for sunscreens has yet to be confirmed
(IARC, 2001). Possible reasons for this
include (i) insufficient application
(Bech-Thomsen and Wulf, 1992; Dif-
fey, 1996), (ii) inadequate immunopro-
tection (Kelly et al., 2003) associated
with poor UVA protection (Fourtanier
et al., 2005), (iii) probable greater use of
sunscreens by high-risk groups, and (iv)
their use/evaluation too late in life to be
prophylactically effective.
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Figure S1. Molecular structures and absorption
spectra of individual and sum of the indivi-
dual spectra combined sunscreens determined
with a UV spectrometer 8453 (Agilent Techno-
logies, AG, Basel, Switzerland) using 3.3 mg
polysilicone-15 and 1.1 mg butyl methoxydiben-
zoylmethane in 100 ml EtOH, respectively,
that matches the ratio of 3:1 in the test for-
mulation.
Table S1. Demographics and just perceptible
MEDs of study volunteers.
Table S2. Antibody details and staining summary.
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